Literature DB >> 15057901

Variation of hepatic glucuronidation: Novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4.

Ursula Ehmer1, Arndt Vogel, Jan Karl Schütte, Britta Krone, Michael P Manns, Christian P Strassburg.   

Abstract

UDP-glucuronosyltransferases are a family of drug metabolizing enzymes contributing to hepatic drug metabolism and protection against environmental toxins. The aim of this study was to identify polymorphisms at the human UGT1A gene locus and to characterize their function and potential association with hepatocellular carcinoma (HCC). Genomic DNA from the blood of 363 subjects (128 patients with HCC, 235 blood donors) was analyzed for polymorphisms of the UGT1A3, UGT1A4, UGT1A8, UGT1A9, UGT1A10 genes using polymerase chain reaction, sequencing analysis. Recombinant variant UGT protein was analyzed by activity assays. In the UGT1A8 gene an A173G variant and a conserved G to A exchange at position 765 were detected in 25% and 15%. UGT1A9 exhibited two variants C3Y and M33T in 1% and 3%. UGT1A10 exhibited conserved nucleotide exchanges (128 G-->A and 696 C-->T) in 2% and 13%. In the UGT1A3 gene a W11R, a V47A variant, and a conserved G to A exchange at position 81 with an incidence of 65%, 58%, and 65%, respectively, were identified. UGT1A4 exhibited a P24T and an L48V variant in 8% and 9%. UGT1A SNPs were not associated with HCC. UGT1A4 P24T and L48V exhibited reduced glucuronidation activities: beta-naphthylamine 30% and 50%, and dihydrotestosterone 50% and 0%, respectively. In conclusion, the high prevalence of SNPs throughout the human UGT1A gene locus illustrates a genetic basis of interindividual variations of hepatic metabolism. Two polymorphisms of the hepatic UGT1A4 protein show a differential metabolic activity toward mutagenic amines and endogenous steroids, altering hepatic metabolism and detoxification.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15057901     DOI: 10.1002/hep.20131

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  50 in total

Review 1.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

Review 2.  Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.

Authors:  Jacqueline Ramírez; Mark J Ratain; Federico Innocenti
Journal:  Future Oncol       Date:  2010-04       Impact factor: 3.404

3.  Perinatal exposure to maternal lamotrigine: clinical considerations for the mother and child.

Authors:  Parvaz Madadi; Shinya Ito
Journal:  Can Fam Physician       Date:  2010-11       Impact factor: 3.275

4.  UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption.

Authors:  Jeannette Zinggeler Berg; Linda B von Weymarn; Elizabeth A Thompson; Katherine M Wickham; Natalie A Weisensel; Dorothy K Hatsukami; Sharon E Murphy
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-05-25       Impact factor: 4.254

5.  Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.

Authors:  Kathryn Kelly Erickson-Ridout; Junjia Zhu; Philip Lazarus
Journal:  Pharmacogenet Genomics       Date:  2011-09       Impact factor: 2.089

6.  Hormones, seizures, and lamotrigine: Oh, my!

Authors:  Page B Pennell
Journal:  Epilepsy Curr       Date:  2008 Jan-Feb       Impact factor: 7.500

7.  In vitro and in vivo glucuronidation of midazolam in humans.

Authors:  Ruth Hyland; Toby Osborne; Anthony Payne; Sarah Kempshall; Y Raj Logan; Khaled Ezzeddine; Barry Jones
Journal:  Br J Clin Pharmacol       Date:  2009-04       Impact factor: 4.335

8.  A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole.

Authors:  Sebastian Frechen; Lisa Junge; Teijo I Saari; Ahmed Abbas Suleiman; Dennis Rokitta; Pertti J Neuvonen; Klaus T Olkkola; Uwe Fuhr
Journal:  Clin Pharmacokinet       Date:  2013-09       Impact factor: 6.447

9.  Frequencies of UGT1A4*2 (P24T) and *3 (L48V) and their effects on serum concentrations of lamotrigine.

Authors:  Arne Reimers; Wenche Sjursen; Grethe Helde; Eylert Brodtkorb
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2014-12-10       Impact factor: 2.441

10.  Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype.

Authors:  Jeannette Zinggeler Berg; Jesse Mason; Angela J Boettcher; Dorothy K Hatsukami; Sharon E Murphy
Journal:  J Pharmacol Exp Ther       Date:  2009-09-28       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.